60 results
6-K
EX-2
BLRX
BioLineRx Ltd.
15 Aug 24
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate
7:06am
granted the order to dismiss without prejudice. The Company also received, on February 5, 2023, a substantially similar lawsuit and motion to approve … the lawsuit as a class action in the Tel Aviv District Court. The total amount claimed in Tel Aviv, if the lawsuit is certified as a class action
6-K
EX-3
BLRX
BioLineRx Ltd.
15 Aug 24
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate
7:06am
, we received a lawsuit and motion to approve the lawsuit as a class action lawsuit pursuant to the Class Action Lawsuits Law 5766-2006, which … , if the lawsuit is certified as a class action, as set forth in the motion is approximately NIS 113.5 million (approximately $32 million). The outcome of the legal
6-K
BLRX
BioLineRx Ltd.
18 Jun 24
Current report (foreign)
4:05pm
agreement with Biokine for motixafortide. The lawsuit seeks compensatory damages in the amount of approximately $6.5 million and a declaratory judgment
6-K
EX-10.1
BLRX
BioLineRx Ltd.
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal
424B5
BLRX
BioLineRx Ltd.
1 Apr 24
Prospectus supplement for primary offering
10:30am
the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal in Israel … in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;
are not liable
20-F/A
8tph ryp2o
26 Mar 24
Annual report (foreign) (amended)
4:57pm
F-3
c4lr2n
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-10.1
s1y5lr fh
21 Sep 22
Current report (foreign)
8:00am
424B5
ldtzyw
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-10.1
hlj56 wj99u
3 Sep 21
Current report (foreign)
4:30pm
424B5
26i67zrfb08yyxd
3 Sep 21
Prospectus supplement for primary offering
4:29pm
POS AM
qo4za ctr0h9bw4pccf
23 Feb 21
Prospectus update (post-effective amendment)
9:12am
6-K
EX-99
abcq1x 8ja
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
424B5
za6hk
21 Jan 21
Prospectus supplement for primary offering
4:31pm
424B5
gpepqdpj
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
nwafzxv 6x6ym5wcf
31 Dec 20
Shelf registration (foreign)
4:37pm
6-K
EX-10.1
hfss r1j6
25 Sep 20
Current report (foreign)
4:33pm
424B5
y3b63k3q5u2
25 Sep 20
Prospectus supplement for primary offering
4:30pm
POS AM
faea3w
10 Aug 20
Prospectus update (post-effective amendment)
12:00am